Syndax Pharmaceuticals, Inc. SNDX
Regular-session close
After hours · Nov 20, 4:01 PM ET
- YTD
- -58.50%
- 1 year
- -48.86%
5D -0.75 (-7.92%)
- Market cap
- 785.05M
- Revenue (ttm)
- 252.25M
- Profit margin
- -87.52%
- EPS (ttm)
- -2.37
- Shares out
- 89.30M
- Forward P/E
- -19.70
- YTD return
- -58.50%
- 1-year return
- -48.86%
- 50-day average
- 17.05
- 200-day average
- 20.20
- Volume
- 2.10M
- Avg volume
- 2.62M
- Open
- 9.14
- Previous close
- 9.13
- Day's range
- 8.69 – 9.27
- 52-week range
- 8.41 – 25.59
- Beta
- 0.45
- Analysts
- Strong Buy
- Price target
- 37.27 (+327.4%)
- Earnings date
- Feb 25, 2027
Key statistics
- Enterprise value
- 1.20B
- Price / sales
- 5.06
- Price / book
- 19.34
- Revenue growth
- 91.80%
- Free cash flow
- -150.08M
- Total cash
- 554.27M
- Total debt
- 589.38M
- Return on equity
- -255.93%
- Short % of float
- 20.51%
Fundamental scorecard
6 of 25 checks passed on SNDX’s reported financials
6of 25 checks passed
- Value 1 of 5
- Growth 3 of 5
- Profitability 1 of 5
- Financial health 1 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 23.00
- Target (mean)
- 37.27
- Target (high)
- 57.00
- Strong buy2
- Buy10
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate -0.48378.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | -0.52 | — | — | — |
| Nov 2, 2026 | Sep 30, 2026 | -0.50408 | -0.55 | -0.05 | -9.11% |
| Aug 4, 2026 | Jun 30, 2026 | -0.44767 | -0.55 | -0.10 | -22.86% |
| Apr 30, 2026 | Mar 31, 2026 | -0.59 | -0.48 | +0.11 | +18.64% |
| Feb 26, 2026 | Dec 31, 2025 | -0.58404 | -0.78 | -0.20 | -33.55% |
| Nov 3, 2025 | Sep 30, 2025 | -0.74 | -0.70 | +0.04 | +5.41% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 3, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Oct 13, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 21, 2026 | UBS | main | Buy | Buy |
| Aug 11, 2026 | JP Morgan | main | Overweight | Overweight |
| Aug 5, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 15, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- syndax.com
News
UBS Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $31
Syndax Pharmaceuticals, Inc. (SNDX) Presents at UBS Global Biopharma Conference 2026 Transcript
12 Health Care Stocks Moving In Wednesday's Intraday Session
Apple To $350? Here Are 10 Top Analyst Forecasts For Tuesday HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $36
Syndax Pharmaceuticals Q3 EPS $(0.55) Misses $(0.49) Estimate, Sales $83.298M Beat $81.850M Estimate
Your note
Sign in to keep a note on SNDX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOTWOOD NICHOLAS A.J. | Officer | Sale | Jun 11, 2026 | 60,885 |
| GALLAGHER NEIL | Officer | Sale | Feb 9, 2025 | 85,095 |
| GOLDAN KEITH ALAN | Chief Financial Officer | Sale | May 31, 2026 | 139,252 |
| HUBER MARTIN H JR | Director | Stock Award(Grant) | Feb 3, 2026 | 103,000 |
| JARRETT A JENNIFER | Director | Stock Award(Grant) | Feb 3, 2026 | 114,000 |
| KATKIN KEITH A | Director | Stock Award(Grant) | Feb 3, 2026 | 124,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 10.18% | 9,020,006 | 128.90M | Jun 29, 2026 |
| Kynam Capital Management, LP | 9.09% | 8,050,959 | 115.05M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 6.61% | 5,861,265 | 83.76M | Jun 29, 2026 |
| State Street Corporation | 6.39% | 5,658,424 | 80.86M | Jun 29, 2026 |
| Bank of America Corporation | 4.57% | 4,045,094 | 57.80M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.43% | 3,927,892 | 56.13M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.19% | 2,823,912 | 40.35M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.87% | 2,547,266 | 36.40M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.59% | 2,296,035 | 32.81M | Sep 29, 2026 |
| Manager Directed Portfolios-Hood River Small-Cap Growth Fund | 1.37% | 1,211,108 | 17.31M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.14% | 1,013,559 | 14.48M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.10% | 973,449 | 13.91M | Aug 30, 2026 |
